A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults

Not Applicable

• Conditions: -A499 Bacterial infection, unspecified; Bacterial infection, unspecified; A499

• Registration Number: PER-063-01
• Lead Sponsor: MERCK SHARP & DOHME PERU S.R.L.,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2001-10-11
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

-Male or female patients age 18 or older
-Patient has a diagnosis of intra-abdominal infection requiring surgery as evidenced by fever, elevated while blood cell count and abdominal pain

Exclusion Criteria

- Patient has another infection, other than abdominal
- Female patient is pregnant or planning to become pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br>Outcome name:That ertapenem is as effective as ceftriaxone/metronidazole in the treatment of an abdominal infection<br>Measure:Efficacy<br>Timepoints:2 weeks after treatment<br>

Secondary Outcome Measures

Name	Time	Method
<br>Outcome name:That ertapenem is as effective as ceftriaxone/metronidazole in the treatment of an abdominal infection<br>Measure:Efficacy<br>Timepoints:4 weeks after treatment<br>